Proteon Therapeutics (NASDAQ:PRTO) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. “

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a “hold” rating and issued a $2.30 target price on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Robert W. Baird restated a “hold” rating and issued a $2.00 target price on shares of Proteon Therapeutics in a research note on Friday, November 10th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $3.20.

Proteon Therapeutics (NASDAQ:PRTO) opened at $1.90 on Thursday. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $2.75. The firm has a market capitalization of $33.48, a P/E ratio of -0.86 and a beta of 1.62.

In other news, Director James E. Flynn acquired 110,557 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were acquired at an average price of $1.75 per share, for a total transaction of $193,474.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders purchased 122,852 shares of company stock worth $216,533. 36.30% of the stock is owned by company insiders.

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC acquired a new stake in Proteon Therapeutics Inc (NASDAQ:PRTO) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics comprises 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd largest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics as of its most recent SEC filing. 50.05% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Proteon Therapeutics (PRTO) Rating Increased to Hold at Zacks Investment Research” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/01/06/proteon-therapeutics-prto-rating-increased-to-hold-at-zacks-investment-research.html.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.